|
Mild cognitive disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diagnosis of dementia at follow-up (obtained using clinical diagnostic criteria) constituted the reference standard, and all the included aMCI patients were divided into two groups: the aMCI converters (MCI-C) and MCI nonconverters (MCI-NC).
|
31744965 |
2020 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Galanin immunohistochemistry was carried out in the anterior nucleus basalis of Meynert of 27 Parkinson's disease (PD) cases without cognitive impairment (mild cognitive impairment [MCI]), 15 with PD with MCI, 42 with Parkinson's disease dementia (PDD), 12 with Dementia with Lewy bodies (DLB), 19 with AD, 12 mixed AD/DLB and 16 controls.
|
31454423 |
2019 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were 38 controls, 26 patients with pure ADCI (18 mild cognitive impairment [MCI] and 8 dementia), 28 patients with pure LBCI (13 MCI and 15 dementia), and 54 patients with mixed ADCI and LBCI (17 MCI and 37 dementia).
|
30944239 |
2019 |
|
Mild cognitive disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We included 768 patients (subjective cognitive decline (SCD, n = 194), mild cognitive impairment (MCI, n = 127), dementia (AD and non-AD, n = 447) with amyloid-β PET and CSF Aβ<sub>42</sub> measurement within 1 year.
|
31810489 |
2019 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated DNA methylation in the <i>APOE</i> gene and apolipoprotein E (ApoE) plasma levels as MCI biomarkers in Colombian subjects with MCI and controls.
|
30897703 |
2019 |
|
Mild cognitive disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we propose a new approach to pathway analysis of blood gene expression profiles to classify healthy (control [CTL]), mildly cognitively impaired (mild cognitive impairment [MCI]; preclinical stage of AD), and AD subjects.
|
31522136 |
2019 |
|
Mild cognitive disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multishell Diffusion magnetic resonance imaging data were acquired from 100 participants (40 cognitively normal, 38 with subjective cognitive decline, and 22 with mild cognitive impairment [MCI]).
|
31467968 |
2019 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Greek traditional dance program was performed where our sample consisted of 30 healthy elderly and 30 with Mild Cognitive Impairment - MCI.
|
30740051 |
2019 |
|
Mild cognitive disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We included 305 memory clinic patients (33% subjective cognitive decline [SCD]: 60 ± 9 years, 61% M; 19% mild cognitive impairment [MCI]: 68 ± 9 years, 68% M; 48% dementia: 66 ± 10 years, 58% M) classified for positivity (±) of amyloid (A) ([<sup>18</sup>F]Florbetaben PET), tau (T) (CSF p-tau), and neurodegeneration (N) (medial temporal lobe atrophy).
|
31597710 |
2019 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study aimed to explore the effect of computerized multi-domain cognitive training (MDCT) on brain gray matter volume and neuropsychological performance in patients with amnestic mild cognitive impairment (amnestic MCI).
|
30705261 |
2019 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
CNNs discriminated c-MCI from s-MCI patients with an accuracy up to 75% and no difference between ADNI and non-ADNI images.
|
30584016 |
2019 |
|
Mild cognitive disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The first cohort comprised 842 participants (513 cognitively unimpaired [CU], 265 with mild cognitive impairment [MCI], and 64 with AD dementia) from the Swedish BioFINDER study.
|
31233127 |
2019 |
|
Mild cognitive disorder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Methods:</b> We enrolled 107 participants (45 amyloid-β-negative cognitively unimpaired [CU-], 7 amyloid-β-positive cognitively unimpaired [CU+], 31 with prodromal AD [mild cognitive impairment; MCI+], and 24 with AD dementia [DEM+]) who completed 2 baseline PET scans (<sup>18</sup>F-flortaucipir and <sup>18</sup>F-florbetaben), MRI, and neuropsychologic tests.
|
30926651 |
2019 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of the current study was to develop an objective tool based on dual-task performance for screening early-stage Alzheimer's disease (AD) and mild cognitive impairment (MCI of the Alzheimer's type).
|
31358792 |
2019 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared Neuropsychiatric Inventory (NPI) total score and NPI subdomain score between mild cognitive impairment-converters (MCI-C) and mild cognitive impairment-nonconverters (MCI-NC) longitudinally for 6 years using the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.
|
31633557 |
2019 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Six hundred fifty patients (median age 68, 58% females) including controls, SCD (subjective cognitive decline), non-amnestic MCI (naMCI), amnestic MCI (aMCI), and AD patients were tested for olfactory dysfunction by means of odor identification testing and semantic memory.
|
30236169 |
2019 |
|
Mild cognitive disorder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Comparison of stable MCI and MCI that progressed to AD showed significantly higher levels in the CSF of MCI patients who progressed to AD, compared to stable MCI patients [SMD: 230.84 (12.54, 449.14), Z = 2.07, P = 0.04].
|
31463927 |
2019 |
|
Mild cognitive disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Secondary efficacy assessments included change from baseline in Clinical Dementia Rating scale-Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog11) and Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL; mild cognitive impairment [MCI] version for prodromal patients) after 12 weeks' treatment.
|
30755255 |
2019 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evidence of inflammation, mitochondrial dysfunction, and oxidative stress prior to the accumulation of amyloid-β in the prodromal stage of AD (mild cognitive impairment; MCI) suggests that early interventions which counteract these features, such as dietary supplements, may ameliorate the onset of MCI-like behavioral symptoms.
|
29914019 |
2018 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
A recently published study using an automated MRI volumetry method (NeuroQuant®) unexpectedly demonstrated larger caudate nucleus volume in patients with Alzheimer's disease dementia (AD) compared to patients with subjective and mild cognitive impairment (SCI and MCI).
|
28741672 |
2018 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
A subsequent analysis of these markers in a cohort of 399 patients (nondemented subjects, patients with mild cognitive impairment [MCI], and patients with AD, supplemented by smaller cohorts of other diseases) was conducted.
|
29482610 |
2018 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the Concord Health and Aging in Men Project, 1705 community-dwelling men aged 70-97 years had detailed baseline clinical assessment of cognitive status (dementia, mild cognitive impairment [MCI] and normal cognition), as well as depression, physical activity, neuromuscular function, health status, sociodemographics, comorbidities, medication use and serum 25 hydroxyvitamin D, 1,25 dihydroxyvitamin D and parathyroid hormone levels.
|
30160054 |
2018 |
|
Mild cognitive disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Leukoaraiosis is one of the main contributors to mild cognitive impairment due to vascular damage (vascular MCI, VMCI), whose pathophysiology has not been fully elucidated yet.
|
30539733 |
2018 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study tested whether resting state alpha rhythms (8-13 Hz) may characterize mild cognitive impairment due to Alzheimer's disease (ADMCI) compared with MCI due to chronic kidney disease (CKDMCI).
|
30103322 |
2018 |
|
Mild cognitive disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to determine the cognitive and functional decline and development of brain injury in individuals progressing from preclinical (β-amyloid positive cognitively normal) to prodromal Alzheimer's disease (AD) (β-amyloid positive mild cognitive impairment [MCI]), and compare this with individuals who progress to MCI in the absence of significant amyloid pathology.
|
29353101 |
2018 |